Pharmaceutical and health care sector : impact of the measures taken in France in the context of COVID-19

Faced with the unprecedented sanitary crisis caused by the COVID-19 epidemic, Article 4 of emergency law n° 2020-290 of 23 March 2020 has created the new legal concept of a health state of emergency and has invoked this health state of emergency for a period of two months coming into force immediately.

In this unique context, this same law authorizes the government to adopt numerous temporary measures by decree of the Prime Minister for the sole purpose of maintaining public health, as well as legislate by ordinances in various areas in order to adapt to the health crisis and its health-related consequences.

The pharmaceutical and health care sector is directly affected, as can be seen day after day in the news, especially due to the nature of the crisis. France is the third country in the world after the United States and China in terms of conducting clinical trials. All stakeholders in the health care system, including industrials, are at the forefront of the fight against this epidemic. It is our responsibility to work as closely as possible with these actors during this period of strain.

This briefing note, which can be accessed through the link below, summarizes and provides regular updates of the essential information for the pharmaceutical and health care sector concerning the timeframes before courts and administrations (1), legislative and regulatory measures relating to health (2) and supplementary measures adopted by other authorities (3). In addition, this document reviews ongoing research towards developing a treatment for COVID-19 (4) and presents the industrial strategies which are in place within the sector.

Please click here to read the full briefing note.


Download PDF Back To Listing
Loading data